Antipodes Partners’s Generate Biomedicines GENB Stock Holding History

Antipodes Partners’s Portfolio GENB Stock Details GENB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$16.2K	Buy	+1,079	New	+$16.6K	﹤0.01%	142

Other funds holding GENB

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

ARK Investment Management St. Petersburg, Florida $17.4B AUM 41.01% 1-Year Est. Return

Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return

Davern Capital Partners Ny, New York $514M AUM 16.9% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Antipodes Partners's GENB Position: Q3 2026 in Review

Antipodes Partners opened a new position in Generate Biomedicines (GENB) in Q3 2026: 1,079 shares worth $16.2K. The stake represents ﹤0.01% of the portfolio and ranks #142 among its holdings.

66 funds tracked by Wall St. Rank hold GENB as of Q3 2026.

Antipodes Partners held 1,079 shares of Generate Biomedicines worth $16.2K as of Q3 2026.
Generate Biomedicines was a new Antipodes Partners position in Q3 2026.
Generate Biomedicines made up ﹤0.01% of Antipodes Partners's portfolio in Q3 2026, its #142 holding.
66 funds tracked by Wall St. Rank held Generate Biomedicines as of Q3 2026.

Based on Antipodes Partners's 13F filing for Q3 2026, filed 5 Nov 2026.